PGNY250117C30000
- 0.05
- 0.000.00%
Progyny Newsroom
Progyny CEO & Director Acquires 136% More Stock
Insider Spends US$3.0m Buying More Shares In Progyny
Progyny Up Over 11%, on Pace for Largest Percent Increase Since February 2023 -- Data Talk
Progyny, Inc. (PGNY): A Bull Case Theory
Executive Chairman David Schlanger Buy 150K Shares of Progyny Common Stock
Progyny up 6% on Insider Buys
Trending Stocks Today | Evaxion Biotech Soars 91.48% Post-Market
Progyny(PGNY.US) Officer Buys US$3.03 Million in Common Stock
Is Now The Time To Look At Buying Progyny, Inc. (NASDAQ:PGNY)?
The Latest Analyst Ratings For Progyny
Progyny Cut to Neutral From Overweight by JP Morgan
Progyny Price Target Cut to $17.00/Share From $22.00 by JP Morgan
J.P. Morgan Downgrades Progyny(PGNY.US) to Hold Rating, Announces Target Price $17
Progyny's Short-Term Challenges and Long-Term Promise: A Hold Rating Amidst Market Pressures
Express News | Progyny Inc : JP Morgan Cuts to Neutral From Overweight
Meridian Hedged Equity Fund Decided to Sell Its Holdings in Progyny (PGNY). Here's Why
Progyny (NASDAQ:PGNY) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Three Years, but the Stock Rallies 11% This Past Week
Here's Why Progyny (PGNY) Was Under Pressure in Q3
Health Care Roundup: Market Talk
Progyny Is Maintained at Overweight by Barclays